Cybin (TSE:CYBN) has released an update.
Cybin Inc., a neuropsychiatry company, is set to participate in the 2024 Milken Institute Future of Health Summit, where CEO Doug Drysdale will discuss cutting-edge mental health treatments. The company is advancing its clinical programs, including CYB003 and CYB004, aimed at addressing major depressive and anxiety disorders.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
